Welcome to our dedicated page for ATRS news (Ticker: ATRS), a resource for investors and traders seeking the latest updates and insights on ATRS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ATRS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ATRS's position in the market.
Antares Pharma reported a 39% revenue increase year-over-year, totaling $45.0 million for Q2 2021, with net income doubling to $4.4 million or $0.03 per share. Key growth drivers included XYOSTED and Teva's generic EpiPen, with total prescriptions for XYOSTED increasing by 50%. The company initiated a PK study for ATRS-1902 after FDA acceptance. They reaffirmed 2021 revenue guidance of $175-200 million, projecting 17%-34% growth.
Antares Pharma (NASDAQ: ATRS) will announce its Q2 2021 financial results on August 5, 2021, before the market opens. A conference call is scheduled for the same day at 8:30 AM ET, with call-in numbers provided for domestic and international participants. Investors can access a live webcast and replay through the Antares Pharma website. The company focuses on developing self-administered injectable products and has established key partnerships with leading pharmaceutical firms. Its products include XYOSTED® and OTREXUP®.
Antares Pharma, Inc. (NASDAQ: ATRS) announced that the FDA has accepted its Investigational New Drug Application for ATRS-1902, aimed at treating acute adrenal insufficiency. This acceptance allows the company to begin a Phase 1 clinical study using an innovative auto-injector for delivering hydrocortisone. The study will compare ATRS-1902's pharmacokinetic profile against Solu-Cortef. Successful completion may lead to a 505(b)(2) NDA filing by the end of 2022, potentially enhancing patient care in emergency situations.
Antares Pharma, a specialty pharmaceutical company, has announced that Robert F. Apple, President and CEO, will present at the Ladenburg Thalmann Annual Healthcare Conference on July 14, 2021, at 2:30 PM ET. The presentation format will include a fireside chat and one-on-one meetings. Interested parties can access the live webcast on the company's website.
Antares Pharma specializes in the development of pharmaceutical products in urology and endocrinology, with FDA-approved offerings including XYOSTED® and OTREXUP®.
Antares Pharma, Inc. (NASDAQ: ATRS) announced the initiation of a Phase 3 study by its partner Idorsia Ltd, evaluating the efficacy of selatogrel for suspected acute myocardial infarction (AMI) using Antares’ Quickshot® auto-injector. This international trial will enroll around 14,000 patients across 250 sites in 30 countries, focusing on deaths and non-fatal AMIs post self-administration. The FDA has granted a Special Protocol Assessment, indicating agreement on the study's design. The partnership could lead to significant market opportunities and potential royalties for Antares upon product approval.
Antares Pharma (NASDAQ: ATRS) has submitted an Investigational New Drug (IND) application to the FDA for ATRS-1902, aimed at treating acute adrenal insufficiency (adrenal crisis) in adults and adolescents. This novel auto-injector platform intends to simplify hydrocortisone delivery during emergencies, contrasting with the cumbersome current standard, Solu-Cortef. The IND application follows positive feedback from the FDA and supports a Phase 1 study comparing ATRS-1902's pharmacokinetics to Solu-Cortef, which will pave the way for a 505(b)(2) NDA filing expected by late 2022.
Antares Pharma, a specialty pharmaceutical company, announced that CEO Robert F. Apple will present at the Raymond James Human Health Innovations Conference on June 22, 2021, at 10:40am ET. The presentation format includes a fireside chat and one-on-one meetings, which will be accessible via live webcast on the company's website. Antares Pharma focuses on developing pharmaceutical products addressing unmet needs in areas such as urology and endocrinology, with a portfolio of FDA-approved products like XYOSTED®, OTREXUP®, and NOCDURNA®.
Antares Pharma, Inc. (NASDAQ: ATRS) announced that CEO Robert F. Apple will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:00 AM ET. The presentation will include a fireside chat and one-on-one meetings. A live webcast will be available on the Antares Pharma website under the 'For Investors' section. Antares Pharma specializes in developing pharmaceutical products in areas like urology and endocrinology, with FDA-approved products including XYOSTED® and OTREXUP®.
Antares Pharma (NASDAQ: ATRS) appointed Joseph V. Renda as Senior Vice President of Commercial, succeeding Patrick Shea. Renda brings extensive experience from leadership roles at Mallinckrodt Pharmaceuticals, Novo Nordisk, and Pfizer, boasting a track record of driving over $1B in sales. CEO Robert F. Apple expressed optimism for Renda's ability to enhance growth, particularly with key products like XYOSTED and NOCDURNA. Renda aims to leverage his background in sales and marketing to capitalize on opportunities in attractive markets while ensuring a smooth transition in leadership.
Antares Pharma reported a strong financial performance for Q1 2021, with revenue increasing by 27% year-over-year to $42.1 million and a net income of $3.8 million, equivalent to $0.02 per share. The growth was driven by a 60% increase in XYOSTED® revenue and a 48% rise in prescriptions for Teva’s generic EpiPen. The company reaffirmed its full-year revenue guidance of $175-200 million, expecting a 17%-34% growth. With enhanced targeting strategies and new leadership appointments, Antares aims to leverage its diverse product portfolio for future growth.
FAQ
What is the market cap of ATRS (ATRS)?
